Silvant Capital Management’s Viking Therapeutics VKTX Stock Holding History

Silvant Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-17,231	Closed	-$416K	–	320
2025 Q1	$416K	Hold	17,231	–	–	0.02%	162
2024 Q4	$693K	Hold	17,231	–	–	0.03%	153
2024 Q3	$1.09M	Hold	17,231	–	–	0.05%	141
2024 Q2	$913K	Hold	17,231	–	–	0.04%	146
2024 Q1	$1.41M	Buy	+17,231	New	+$767K	0.07%	137

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Silvant Capital Management's VKTX Position: Q2 2025 in Review

Silvant Capital Management sold out of Viking Therapeutics (VKTX) in Q2 2025, closing a stake of 17,231 shares — an estimated $416K sold.

Silvant Capital Management first reported a position in VKTX in Q1 2024 and held it in 5 quarters. The position peaked at $1.41M in Q1 2024. 392 funds tracked by Wall St. Rank hold VKTX as of Q2 2025.

Silvant Capital Management reported no remaining Viking Therapeutics position as of Q2 2025 after selling out during the quarter.
Silvant Capital Management sold 17,231 Viking Therapeutics shares in Q2 2025, an estimated $416K.
Silvant Capital Management first reported a position in Viking Therapeutics in Q1 2024 and held it in 5 quarters.
Silvant Capital Management's Viking Therapeutics position peaked at $1.41M in Q1 2024.
392 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2025.

Based on Silvant Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.